Fenretinide (4-HPR) in chemoprevention of oral leukoplakia
- 1 January 1993
- journal article
- clinical trial
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 53 (S17F) , 255-261
- https://doi.org/10.1002/jcb.240531038
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary resultsOral Oncology, 1992
- Long-term tolerability of fenretinide (4-HPR) in breast cancer patientsEuropean Journal of Cancer and Clinical Oncology, 1991
- Response of oral leukoplakia to beta-carotene.Journal of Clinical Oncology, 1990
- Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 1990
- Follow-up of Oral Leukoplakia After Carbon Dioxide Laser SurgeryJAMA Otolaryngology–Head & Neck Surgery, 1990
- 13-cis-Retinoic Acid in the Treatment of Oral LeukoplakiaNew England Journal of Medicine, 1986
- Effect of retinoids on oral leukoplakiaThe American Journal of Surgery, 1983
- Tables of the number of patients required in clinical trials using the logrank testStatistics in Medicine, 1982
- Biochemical treatment of precancerous oral lesions: The effectiveness of various analogues of retinoic acidJournal of Maxillofacial Surgery, 1978